Lawrence Eichenfield

3 weeks ago | dermatologytimes.com | Emma Andrus |Lawrence Eichenfield

In a continued conversation with Dermatology Times, Lawrence (Larry) Eichenfield, MD, vice chair of dermatology and professor of dermatology and pediatrics at the University of California, San Diego, expanded on the pivotal ICONIC-LEAD phase 3 studyand what the emerging data on icotrokinra (JNJ-2113)1 may mean for the future of adolescent plaque psoriasis management.

4 weeks ago | dermatologytimes.com | Emma Andrus |Lawrence Eichenfield

New data from Johnson & Johnson’s phase 3 ICONIC-LEAD study suggest promise in the treatment of moderate to severe plaque psoriasis in adolescents. Icotrokinra (JNJ-2113), an investigational, first-in-class oral peptide that selectively targets the IL-23 receptor, demonstrated strong efficacy and a favorable safety profile in this population. In the adolescent cohort, 84.1% achieved clear or almost clear skin (IGA 0/1) by week 16, compared to just 27.3% in the placebo group.

Jun 27, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 27, 2024A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Jun 21, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 20, 2024Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

Jun 13, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 13, 2024An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers. Video content above is prompted by the following question(s):How do the study findings align with your own clinical experiences and observations in managing patients with atopic dermatitis (AD)?